Main contents starts here
Press Releases 2008
- September 2, 2008
Appointment of New CEO of Takeda Pharmaceuticals Europe Limited - August 29, 2008
Takeda and Affymax Provide Clinical Development Update for Hematide™ in Chemotherapy-induced Anemia
– Companies Decide to Suspend Co-Development of Hematide™ in CIA and Focuses all Efforts on Late Stage Co-Development in Chronic Renal Failure Related Anemia – - July 16, 2008
Antiosteoporotic drugs “Actonel® 17.5 mg tablets” and “Benet® 17.5 mg tablets” received approval for additional indication in patients with Paget’s disease of bone: Both come in new packages. - July 14, 2008
Notice Concerning the Determination of the Items of Stock Options (Stock Acquisition Rights) for Members of the Board of Directors - July 8, 2008
Takeda Submitted a Request for Mutual Agreement Procedure Regarding a Correction Notice Based on Transfer Pricing Taxation - July 2, 2008
Takeda Pharmaceuticals and TAP Pharmaceutical Products Inc. Merge
Combined Company is a Top 15 Pharmaceutical Company in the United States - June 30, 2008
Launch of “ENBREL® 25mg Syringe 0.5 mL for S.C. Injection” New Formulation of ENBREL® - June 30, 2008
Takeda Submitted a New Drug Application for Anti-Cancer Agent, panitumumab (recombinant) - June 26, 2008
Notice Concerning Stock Options (Stock Acquisition Rights) for Members of the Board of Directors - June 24, 2008
Notice Concerning Cancellation of Own Shares - June 24, 2008
Notice of Execution of Acquisition of the Company’s Own Shares - June 23, 2008
FDA Approves VELCADE® (BORTEZOMIB) for Injection for Patients with Previously Untreated Multiple Myeloma
-- New indication offers earlier treatment options for patients -- - June 17, 2008
Takeda to Appeal EMEA Negative Opinion on ramelteon for the Treatment of Primary Insomnia - June 9, 2008
Phase 3 Results for alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
Data from five pivotal phase 3 studies presented at the American Diabetes Association 68th Scientific Sessions - May 27, 2008
Takeda to Support Relief Effort for Earthquake Disaster in the southwest province of Sichuan, China
Takeda employees around the world express their deepest sympathy and condolences to all those affected by this disaster. - May 27, 2008
Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics - May 26, 2008
Voglibose (BASEN®) for the prevention of type 2 diabetes mellitus: A Randomized, Double-blind Trial in Japanese Subjects with Impaired Glucose Tolerance
--- Data Presented at The 51st Annual Meeting of the Japan Diabetes Society --- - May 16, 2008
Proposed Amendments of the Remuneration System For Members of Board of Directors and Corporate Auditors - May 15, 2008
Takeda Completes Acquisition of Millennium - May 15, 2008
Takeda Completes Subsequent Offering Period for Shares of Millennium Pharmaceuticals, Inc. - May 9, 2008
Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period - May 9, 2008
Notice regarding Acquisition of the Company’s own shares
(Under the provisions of Articles of Incorporation pursuant to Article 165 (2) of the Corporation Law of Japan) - May 1, 2008
Abbott, Takeda Conclude TAP Joint Venture - April 30, 2008
Sucampo Pharmaceuticals Obtains FDA Approval for AMITIZA® for the Treatment of Irritable Bowel Syndrome with Constipation in Adult Women
Sucampo Pharmaceuticals’ Second Consecutive Successful FDA Approval for AMITIZA; 8 mcg Dose to Fill the Void in the Currently Available Therapies for IBS-C in Adult Women - April 25, 2008
Notice Concerning Cancellation of Own Shares - April 25, 2008
Notice of Execution of Acquisition of the Company’s Own Shares - April 10, 2008
Notice regarding Acquisition of the Company’s own shares
(Under the provisions of Articles of Incorporation pursuant to Article 165 (2) of the Corporation Law of Japan) - April 10, 2008
Takeda to Acquire Millennium for Us$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
-- Acquisition Accelerates Takeda’s Vision of Becoming a Global Leader in Oncology -- - April 4, 2008
Takeda Wins Definitive Decision in Patent Infringement Litigation on Appeal against an ANDA Filer for Generic ACTOS® - April 1, 2008
Transfer of Shares of Hitachi Inspharma, Ltd. from Takeda to Hitachi - April 1, 2008
Launch of Takeda Bio Development Center Limited - April 1, 2008
New Data Showed ACTOS® (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients with Type 2 Diabetes
Data expands body of evidence in high risk population using IVUS, a unique marker for coronary atherosclerosis - April 1, 2008
Cell Genesys and Takeda Announce Global Alliance for the Development and Commercialization of GVAX Immunotherapy for Prostate Cancer - March 31, 2008
Sharing of Sabin-IPV Seed Virus by Japan Poliomyelitis Research Institute with Takeda and Grant of Right to Its Commercialization - March 28, 2008
Discontinuation of Development of TAK-475, A Compound for Treatment of Hypercholesterolemia - March 20, 2008
Announcement on the Restructuring of U.S. Operations - March 20, 2008
Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
Companies to Evenly Divide Value of TAP - March 17, 2008
Takeda Submitted a New Drug Application for a Fixed Dose Combination Tablet of Blopress® with Diuretic in Japan for Treatment of Hypertension - February 29, 2008
Takeda Submitted a New Drug Application for Ramelteon in Japan for Treatment of insomnia - February 18, 2008
Takeda Discontinues Development of Matuzumab - February 4, 2008
Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates - January 25, 2008
Takeda Doses First Patient in A U.S. Phase 1 Study of Hematide™ to Treat Chemotherapy Induced Anemia - January 4, 2008
Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. - January 4, 2008
TAP Pharmaceutical Products Inc. Filed New Drug Application for TAK-390MR in Patients with Acid-Related Disorders